CCIA
BPMC

Campbell & Co Investment Adviser’s Blueprint Medicines BPMC Stock Holding History

Campbell & Co Investment Adviser’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,060
Closed -$877K – 1049
2024
Q4 		$877K Sell
10,060
-9,587
-49% -$878K 0.07% 439
2024
Q3 		$1.82M Buy
19,647
+14,585
+288% +$1.45M 0.14% 218
2024
Q2 		$546K Buy
+5,062
New +$507K 0.05% 620

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Campbell & Co Investment Adviser's BPMC Position: Q1 2025 in Review

Campbell & Co Investment Adviser sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 10,060 shares — an estimated $877K sold.

Campbell & Co Investment Adviser first reported a position in BPMC in Q2 2024 and held it in 3 quarters. The position peaked at $1.82M in Q3 2024. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • Campbell & Co Investment Adviser reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 10,060 Blueprint Medicines shares in Q1 2025, an estimated $877K.
  • Campbell & Co Investment Adviser first reported a position in Blueprint Medicines in Q2 2024 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Blueprint Medicines position peaked at $1.82M in Q3 2024.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2025, filed 14 May 2025.